I-Mab (IMAB) News Today $2.62 +0.61 (+30.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.54 -0.08 (-2.86%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Everest Medicines announces strategic equity investment in I-MabAugust 1 at 2:45 PM | msn.comEverest Medicines Expands Strategic Investment in I-MABAugust 1 at 8:56 AM | prnewswire.comI-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary SharesAugust 1 at 8:00 AM | globenewswire.comI-Mab (NASDAQ:IMAB) Lowered to "Hold" Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge HealthJuly 17, 2025 | globenewswire.comI-Mab to Present at the BTIG Virtual Biotechnology ConferenceJuly 14, 2025 | finance.yahoo.comI-Mab (NASDAQ:IMAB) Raised to Buy at Wall Street ZenJuly 12, 2025 | marketbeat.comI-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025July 9, 2025 | msn.comI-Mab (NASDAQ:IMAB) Given Buy Rating at HC WainwrightJuly 9, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for I-Mab (NASDAQ:IMAB)July 9, 2025 | marketbeat.comI-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - NasdaqJuly 4, 2025 | nasdaq.comI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025July 2, 2025 | globenewswire.comI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - MorningstarJuly 2, 2025 | morningstar.comMI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchJune 30, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Price Target Raised to $5.00June 27, 2025 | marketbeat.comI-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025June 26, 2025 | globenewswire.comI-Mab Biopharma: I-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 13, 2025 | finanznachrichten.deI-Mab Regains Nasdaq Compliance with Minimum Bid PriceJune 12, 2025 | tipranks.comI-Mab regains Nasdaq compliance as shares maintain $1 minimum bidJune 12, 2025 | investing.comI-Mab to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 3, 2025 | finance.yahoo.comI-Mab Advances Givastomig in Gastric Cancer with Promising Clinical DataJune 2, 2025 | tipranks.comI-Mab stock surges on Lucid Capital’s buy rating initiationMay 29, 2025 | za.investing.comI-Mab (NASDAQ:IMAB) Shares Up 5.1% - Here's What HappenedMay 29, 2025 | marketbeat.comI-Mab stock surges on Lucid Capital's buy rating initiationMay 28, 2025 | investing.comI-Mab to Present at Jefferies Global Healthcare Conference and Share New Givastomig Data at ESMO GI Cancers Congress 2025May 21, 2025 | nasdaq.comI-Mab to Present at Jefferies Global Healthcare ConferenceMay 20, 2025 | globenewswire.comI-Mab’s Financial Report Highlights Givastomig ProgressMay 16, 2025 | tipranks.comI-Mab’s Promising Clinical Developments and Financial Stability Earn ‘Buy’ Rating from AnalystMay 15, 2025 | tipranks.comI-Mab (NASDAQ:IMAB) Shares Sold by Hhlr Advisors LTD.May 1, 2025 | marketbeat.comI-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025April 30, 2025 | gurufocus.comI-Mab (NASDAQ:IMAB) Short Interest Down 64.9% in MarchApril 17, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for I-Mab (NASDAQ:IMAB) Stock PriceApril 6, 2025 | marketbeat.comI-Mab's (IMAB) Buy Rating Reiterated at Needham & Company LLCApril 6, 2025 | marketbeat.comI-Mab’s Transformative Year: Financial and Strategic HighlightsApril 4, 2025 | tipranks.comI-Mab price target lowered to $7 from $8 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comI-Mab Positions for Growth with U.S. Focus and Innovative Cancer TreatmentsApril 4, 2025 | tipranks.comI-Mab Reports Full Year 2024 Financial Results and Provides Business UpdateApril 3, 2025 | gurufocus.comI-Mab stock touches 52-week low at $0.72 amid market challengesApril 3, 2025 | investing.comI-Mab (NASDAQ:IMAB) Trading 0.6% Higher - Still a Buy?March 28, 2025 | marketbeat.comI-Mab to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | markets.businessinsider.comI-Mab faces Nasdaq delisting over bid price ruleMarch 23, 2025 | investing.comI-Mab receives Nasdaq deficiency noticeMarch 22, 2025 | markets.businessinsider.comI-Mab Receives Nasdaq Deficiency Notice for Minimum Bid PriceMarch 21, 2025 | tipranks.comI-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMarch 21, 2025 | globenewswire.comShort Interest in I-Mab (NASDAQ:IMAB) Rises By 20.0%March 7, 2025 | marketbeat.comI-Mab Biopharma: I-Mab Announces Accelerated Givastomig Phase 1b Study ProgressMarch 7, 2025 | finanznachrichten.deI-Mab Completes Enrollment Ahead of Schedule in First Dose Expansion Cohort of Givastomig Study, Doses First Patient in Second CohortMarch 7, 2025 | quiverquant.comQI-Mab Announces Accelerated Givastomig Phase 1b Study ProgressMarch 7, 2025 | globenewswire.comI-Mab (IMAB) Projected to Post Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Upgraded to Strong-Buy at Brookline Capital ManagementMarch 2, 2025 | marketbeat.com Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address IMAB Media Mentions By Week IMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMAB News Sentiment▼0.000.45▲Average Medical News Sentiment IMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMAB Articles This Week▼32▲IMAB Articles Average Week Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Maravai LifeSciences News MeiraGTx News Phathom Pharmaceuticals News Autolus Therapeutics News Xencor News Valneva News Relay Therapeutics News Bicara Therapeutics News Organogenesis News Septerna News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMAB) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
